Hudson BI[Author] - Search Results

Year	Number of Results
1998	1
2001	3
2002	1
2003	3
2004	2
2005	7
2006	1
2007	2
2008	4
2009	5
2010	3
2011	2
2012	1
2013	1
2014	2
2015	2
2016	3
2017	4
2018	1
2019	1
2022	2
2023	2
2024	0

1

Targeting RAGE Signaling in Inflammatory Disease.

Hudson BI, Lippman ME. Hudson BI, et al. Annu Rev Med. 2018 Jan 29;69:349-364. doi: 10.1146/annurev-med-041316-085215. Epub 2017 Nov 6. Annu Rev Med. 2018. PMID: 29106804 Review.

2

RAGE inhibitor TTP488 (Azeliragon) suppresses metastasis in triple-negative breast cancer.

Magna M, Hwang GH, McIntosh A, Drews-Elger K, Takabatake M, Ikeda A, Mera BJ, Kwak T, Miller P, Lippman ME, Hudson BI. Magna M, et al. Among authors: hudson bi. NPJ Breast Cancer. 2023 Jul 13;9(1):59. doi: 10.1038/s41523-023-00564-9. NPJ Breast Cancer. 2023. PMID: 37443146 Free PMC article.

3

Alternative splicing of RAGE: roles in biology and disease.

Kalea AZ, Schmidt AM, Hudson BI. Kalea AZ, et al. Among authors: hudson bi. Front Biosci (Landmark Ed). 2011 Jun 1;16(7):2756-70. doi: 10.2741/3884. Front Biosci (Landmark Ed). 2011. PMID: 21622207 Free article. Review.

4

Soluble RAGE: a hot new biomarker for the hot joint?

Moser B, Hudson BI, Schmidt AM. Moser B, et al. Among authors: hudson bi. Arthritis Res Ther. 2005;7(4):142-4. doi: 10.1186/ar1764. Epub 2005 Jun 3. Arthritis Res Ther. 2005. PMID: 15987496 Free PMC article.

5

Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy.

Wendt T, Tanji N, Guo J, Hudson BI, Bierhaus A, Ramasamy R, Arnold B, Nawroth PP, Yan SF, D'Agati V, Schmidt AM. Wendt T, et al. Among authors: hudson bi. J Am Soc Nephrol. 2003 May;14(5):1383-95. doi: 10.1097/01.asn.0000065100.17349.ca. J Am Soc Nephrol. 2003. PMID: 12707408 Review.

6

Comment on "The lingering mysteries of metastatic recurrence in breast cancer".

Hudson BI, Lippman ME. Hudson BI, et al. Br J Cancer. 2023 Feb;128(3):484-485. doi: 10.1038/s41416-022-02012-0. Epub 2022 Oct 31. Br J Cancer. 2023. PMID: 36316559 Free PMC article. No abstract available.

7

Diabetic vascular disease: it's all the RAGE.

Hudson BI, Wendt T, Bucciarelli LG, Rong LL, Naka Y, Yan SF, Schmidt AM. Hudson BI, et al. Antioxid Redox Signal. 2005 Nov-Dec;7(11-12):1588-600. doi: 10.1089/ars.2005.7.1588. Antioxid Redox Signal. 2005. PMID: 16356122 Review.

8

Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases.

Maillard-Lefebvre H, Boulanger E, Daroux M, Gaxatte C, Hudson BI, Lambert M. Maillard-Lefebvre H, et al. Among authors: hudson bi. Rheumatology (Oxford). 2009 Oct;48(10):1190-6. doi: 10.1093/rheumatology/kep199. Epub 2009 Jul 9. Rheumatology (Oxford). 2009. PMID: 19589888 Review.

9

Receptor for advanced glycation end products and its ligands: a journey from the complications of diabetes to its pathogenesis.

Kim W, Hudson BI, Moser B, Guo J, Rong LL, Lu Y, Qu W, Lalla E, Lerner S, Chen Y, Yan SS, D'Agati V, Naka Y, Ramasamy R, Herold K, Yan SF, Schmidt AM. Kim W, et al. Among authors: hudson bi. Ann N Y Acad Sci. 2005 Jun;1043:553-61. doi: 10.1196/annals.1338.063. Ann N Y Acad Sci. 2005. PMID: 16037278 Review.

10

RAGE: a novel biological and genetic marker for vascular disease.

Kalea AZ, Schmidt AM, Hudson BI. Kalea AZ, et al. Among authors: hudson bi. Clin Sci (Lond). 2009 Apr;116(8):621-37. doi: 10.1042/CS20080494. Clin Sci (Lond). 2009. PMID: 19275767 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

49 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Results by year